Ballicules.com

Cefixime

SUPRAX

What it isOral PBP-inhibiting third-generation cephalosporin; susceptible urinary and respiratory infections.

Why this oneIt offers convenient oral Gram-negative coverage but lacks the antipseudomonal reach of ceftazidime.

What limits itFor gonorrhea it is an alternative only when ceftriaxone is unavailable; poor staphylococcal coverage, diarrhea, and renal adjustment also matter.

FDA-approved for

FDA label

FDA dosingPopulationStartTargetMax
General infectionsAdults400 mg/day (single or 200 mg q12h)400 mg/day400 mg/day
Uncomplicated cervical/urethral gonorrheaAdults400 mg single dose400 mg single dose400 mg
S. pyogenes infectionAdults400 mg/day ≥10 days400 mg/day400 mg/day
General infections (use suspension)Children ≥6 mo8 mg/kg/day QD or 4 mg/kg q12h8 mg/kg/day400 mg/day (>45 kg or >12 y: adult dose)

Renal CrCl ≥60: normal dose. Adjust for CrCl <60 (CrCl 21–59 or hemodialysis ≈65% of dose; ≤20 or CAPD ≈50%). Dialysis does not remove significant drug

Hepatic Undefined

Instructions

Cautions

Adverse reactions

Pregnancy No established drug-associated risks of major birth defects or miscarriage; no evidence of fetal harm in animals

Lactation No human data; present in animal milk and likely present in human milk

NO BOXED WARNINGS

Principal riskNo longer recommended for gonorrhea; poor staphylococcal cover

Cost, est. cash$10–$300/month

Generic entry2004

Classes and tags

Clinical profile

Therapeutic safety burden1 / 4
Overdose danger1 / 4
Weight-gain liability0 / 4
Sedation liability0 / 4
QT / Torsades0 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk0 / 4

Legacy pregnancy categoryB

Defining liabilityAllergy, gastrointestinal effects and agent-specific renal, hepatic, hematologic or interaction risks.

Mechanism of action: Cefixime ballicule

Cefixime ballicule: receptor binding, kinetics and half-life diagram

Open Cefixime in the interactive console ↗